scholarly journals Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1336
Author(s):  
Angiolo Gadducci ◽  
Stefania Cosio
Keyword(s):  
Ovarian Carcinoma ◽  
Endocrine Therapy ◽  
Biological Behavior ◽  
Lower Sensitivity ◽  
Low Grade ◽  
Targeted Agents ◽  
Mek Inhibitors ◽  
Serous Ovarian Carcinoma ◽  
Fertility Sparing ◽  
Molecularly Targeted Agents

Low-grade serous ovarian carcinoma (LGSOC) is a distinct pathologic and clinical entity, characterized by less aggressive biological behavior, lower sensitivity to chemotherapy and longer survival compared with high-grade serous ovarian carcinoma. LGSOC often harbors activating mutations of genes involved in mitogen activated protein kinase (MAPK) pathway. Patients with disease confined to the gonad(s) should undergo bilateral salpingo-oophorectomy, total hysterectomy and comprehensive surgical staging, although fertility-sparing surgery can be considered in selected cases. Women with stage IA-IB disease should undergo observation alone after surgery, whereas observation, chemotherapy or endocrine therapy are all possible options for those with stage IC-IIA disease. Patients with advanced disease should undergo primary debulking surgery with the aim of removing all macroscopically detectable disease, whereas neoadjuvant chemotherapy followed by interval debuking surgery. After surgery, the patients can receive either carboplatin plus paclitaxel followed by endocrine therapy or endocrine therapy alone. Molecularly targeted agents, and especially MEK inhibitors and Cyclin-dependent kinase (CDK) inhibitors, are currently under evaluation. Additional research on the genomics of LGSOC and clinical trials on the combination of MEK inhibitors with hormonal agents, other molecularly targeted agents or metformin, are strongly warranted to improve the prognosis of patients with this malignancy.

scholarly journals Trends of low-grade serous ovarian carcinoma in the United States

2018 ◽  
Vol 29 (1) ◽  
Author(s):  
Koji Matsuo ◽  
Hiroko Machida ◽  
Brendan H. Grubbs ◽  
Anil K. Sood ◽  
David M. Gershenson
Keyword(s):  
United States ◽  
Ovarian Carcinoma ◽  
The United States ◽  
Low Grade ◽  
Serous Ovarian Carcinoma

scholarly journals Low-grade Serous Ovarian Carcinoma

2018 ◽  
Vol 78 (10) ◽  
pp. 972-976 ◽  
Author(s):  
Enzo Ricciardi ◽  
Thaïs Baert ◽  
Beyhan Ataseven ◽  
Florian Heitz ◽  
Sonia Prader ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Ovarian Carcinoma ◽  
Systemic Treatment ◽  
Hormonal Treatment ◽  
Current Treatment ◽  
Low Grade ◽  
Separate Entity ◽  
Serous Ovarian Carcinoma ◽  
Number Of Patients

AbstractIn the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.

Low-grade serous ovarian carcinoma: an evolution toward targeted therapy

2019 ◽  
Vol 30 (10) ◽  
pp. 1619-1626 ◽  
Author(s):  
Ioannis A Voutsadakis
Keyword(s):  
Clinical Trials ◽  
Targeted Therapy ◽  
Ovarian Carcinoma ◽  
Molecular Profile ◽  
Low Grade ◽  
High Grade ◽  
Novel Therapies ◽  
Precursor Lesions ◽  
Molecular Defects ◽  
Serous Ovarian Carcinoma

Low-grade serous ovarian carcinoma and its high-grade serous ovarian carcinoma counterpart differ in their precursor lesions, molecular profile, natural history, and response to therapies. As such, low-grade serous ovarian carcinoma needs to be studied separately from high-grade serous ovarian carcinoma, despite challenges stemming from its rarity. A deeper understanding of the pathogenesis of low-grade serous ovarian carcinoma and the most common molecular defects and pathways involved in the carcinogenesis of the ovarian epithelium from normal to serous borderline ovarian tumors to low-grade serous ovarian carcinoma will help develop better therapies. By adopting targeted approaches there may be an opportunity to integrate novel therapies without the need for robust numbers in clinical trials. This manuscript will discuss low-grade serous ovarian carcinoma and focus on the arising treatments being developed with an improved understanding of the pathogenesis of this disease.

Use of adjuvant chemotherapy for early-stage low-grade serous ovarian carcinoma

2020 ◽  
Vol 159 ◽  
pp. 61
Author(s):  
J.K. Oh ◽  
D. Nasioudis ◽  
S. Gysler ◽  
E.M. Ko ◽  
M.A. Morgan ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Early Stage ◽  
Low Grade ◽  
Serous Ovarian Carcinoma

scholarly journals Ultrasound, macroscopic and histological features of serous epithelial ovarian carcinomas

2020 ◽  
pp. ijgc-2020-001473
Author(s):  
Paola Romeo ◽  
Damiano Arciuolo ◽  
Maria Cristina Moruzzi ◽  
Francesca Moro
Keyword(s):  
Ovarian Carcinoma ◽  
Low Grade ◽  
High Grade ◽  
Ovarian Carcinomas ◽  
Histological Features ◽  
Serous Ovarian Carcinoma ◽  
Epithelial Ovarian Carcinomas

We present a video showing two cases of serous epithelial ovarian carcinomas. The first video shows clinical, ultrasound, macroscopic, and histological features of a patient with high grade serous ovarian carcinoma. The second video presents clinical, ultrasound, macroscopic, and histological features of a patient with low grade serous ovarian carcinoma.

Low grade serous ovarian carcinoma with metastases to the sternum and ribs

Pathology ◽  
2012 ◽  
Vol 44 (5) ◽  
pp. 481-482
Author(s):  
Sophie McGrath ◽  
Thumuluru Kavitha Madhuri ◽  
Sree Susarla ◽  
Ben Haagsma ◽  
Farid Saleh ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Low Grade ◽  
Serous Ovarian Carcinoma

Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 5543-5543
Author(s):  
Yang Xiang ◽  
Shan Zhu ◽  
Weiran Wang ◽  
Dongyan Cao ◽  
Xi-Run Wan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Carcinoma ◽  
Epithelial Ovarian Cancer ◽  
Circulating Tumor Dna ◽  
Stage Iii ◽  
Signal Pathways ◽  
Low Grade ◽  
Serous Ovarian Carcinoma ◽  
Ctdna Analysis ◽  
Tumor Dna

5543 Background: Circulating tumor DNA (ctDNA) analysis in epithelial ovarian cancer (EOC) was previously reported, however with limited samples or limited genes. Here, we reported an analysis of ctDNA in EOC cohort using targeted sequencing with a 1021-gene panel. Methods: Patients with EOC were enrolled, and treatment-naïve tumor tissues and blood samples were collected. We utilized a 1021-gene NGS panel in matched tissue DNA and ctDNA to identify somatic mutations with white blood cell DNA as a germline control. Results: Mutations were identified in all of the 65 tissues and in 53 (81.5%) ctDNA. The median ctDNA mutation allelic frequency was 2.5%, ranging from 0.1% to 36.2%. A median of 66.7% (12.5%-100.0%) of tissue derived mutations were observed in ctDNA. Besides, there were 91 ctDNA private mutations, including TP53 gene mutations. The most frequently mutated genes were TP53 (55.4%), PIK3CA (13.8%) and ARID1A (12.3%) in ctDNA analysis, which were consistent with tissue analysis (60.0%, 26.2% and 20.0% of tissues with TP53, PIK3CA and ARID1A mutations, respectively). Mutations of TP53 (37/42) in high-grade serous ovarian carcinoma (HGSOC), PIK3CA (10/11) and ARID1A (8/11) in ovarian clear cell carcinoma, BRAF (4/5) in low-grade serous ovarian carcinoma and PIK3CA (3/5), ARID1A (2/5) and PTEN (2/5) in endometrioid carcinoma were observed as the most commonly genetic aberrations in ctDNA in different sub-types of EOC, which located in different signal pathways and suggested different pathogenesis. In total, 90.5% (38/42) of HGSOC were ctDNA positive, comparing with 65.2% (15/23) of other EOC subtypes (p = 0.012). In addition, 56.5% (13/23) of stage I~II EOC were ctDNA positive, comparing with 94.7% (36/38) of stage III (p = 0.002). No association between ctDNA positivity and other clinic characteristics was observed, including pathological differentiation, CA125, lesion density (solid vs. cystic-solid and cystic). Multivariable analysis suggested FIGO stage III (p = 0.008) as an independent predictor of ctDNA detection. Conclusions: In summary, genomic characterization of EOC may offer insights into tumorigenesis and identify potential therapeutic targets in this disease.

Sign in / Sign up

Export Citation Format

Share Document